<DOC>
	<DOCNO>NCT01758393</DOCNO>
	<brief_summary>This randomize , open-label , single-center clinical trial compare efficacy safety profile medium-dose versus high dose glucocorticoid patient IgG4-related Disease . Patients follow three month measure primary outcome secondary outcome .</brief_summary>
	<brief_title>Glucocorticoids Patients With IgG4-RD</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Males female Age 1870 year old informed consent Patients IgG4RD : 1. swelling , sclerosing inflammatory involvement one organ , include sclerosing pancreatitis , sclerosing cholangitis , inflammatory pseudotumors , retroperitoneal mediastinal fibrosis , interstitial nephritis , hypophysitis , sclerosing dacryoadenitis , sialadenitis , inflammatory aortic aneurysm , lymphadenopathy , inflammatory condition ; 2. elevate serum IgG4 ( &gt; 1.35 g/L ) 3. histopathologic feature fibrosis and/or lymphocytic polyclonal plasma cell infiltration ( IgG4+ plasma cell immunohistology perform ) ; 4. exclusion disease . Previously currently receive glucocorticoid ( ) immunomodulator Pregnancy lactate Concurrent severe and/or uncontrolled and/or unstable disease Patient malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>IgG4-related disease</keyword>
	<keyword>IgG4-RD</keyword>
</DOC>